- Company
- ZP Therapeutics appoints Junghun Kim as new head
- by Eo, Yun-Ho Apr 8, 2025 05:57am
- The head of ZP&160;Therapeutics has been replaced after about 3 months. According to industry sources, Zuellig Pharma Korea recently appointed Junghun Kim (50), former Country Manager of Takeda Pharmaceutical Malaysia and Singapore, as the new General Manager of its commercial division, ZP Therapeutics. Hyunjoo Lee (48), the former CE
- Company
- China's mAb 'Hetronifly' secures orphan drug designation
- by Eo, Yun-Ho Apr 7, 2025 05:51am
- China-made immune checkpoint inhibitor has been designated as an orphan drug in South Korea. The Ministry of Food and Drug Safety (MFDS) recently announced on a notification board that it has granted Shanghai Henlius Biotech's 'Hetronifly (serplulima)' an orphan drug designation (ODD). The drug is indicated for 'use in combination with
- Company
- AbbVie Korea sales up twofold in two years
- by Son, Hyung Min Apr 7, 2025 05:51am
- With its new drugs for immune diseases, AbbVie Korea's sales have reportedly increased twofold in two years. AbbVie Korea is successfully transitioning generational changes for Humira follow-up of new drugs, including Skyrizi and Rinvoq. According to the Financial Supervisory Service on April 4, AbbVie recorded KRW 308.9 billion last year, up
- Company
- GPP drug Spevigo can be prescribed in general hospitals
- by Eo, Yun-Ho Apr 7, 2025 05:51am
- 'Spevigo', a treatment for Generalized Pustular Psoriasis (GPP), may now be prescribed in general hospitals in Korea. According to industry sources, the new drug for generalized pustular psoriasis (GPP) from Boehringer Ingelheim Korea, Spevigo (spesolimab), has recently passed the Drug Committee (DC) of the Seoul National University Hospi
- Company
- K-pharma trials show greenlight overcoming bile duct cancer
- by Son, Hyung Min Apr 4, 2025 05:58am
- South Korean and the overseas pharmaceutical industry's candidate products that are targeted anticancer agents for bile duct cancer (cholangiocarcinoma) are showing results of effectiveness, indicating the potential for commercialization possibilities. Korean and overseas pharmaceutical companies, including Handok's US partner Compass Therapeuti
- Company
- Obesity drug craze affects global pharma subsidiaries in KOR
- by Son, Hyung Min Apr 4, 2025 05:58am
- Whether or not a new obesity drug in the glucagon-like peptide (GLP-1) family has been launched has had a significant impact on the performance of Novo Nordisk and Lilly Korea. Last year, Novo Nordisk’s sales increased by 63% upon the launch of Wegovy in the domestic market. In the case of Lilly Korea, sales decreased slightly due to the delay
- Company
- New drug 'Niktimvo' for cGVHD receives ODD in Korea
- by Eo, Yun-Ho Apr 4, 2025 05:58am
- 'Niktimvo,' a new drug for the treatment of chronic graft-versus-host disease (cGVHD), has been designated as an orphan drug in South Korea. The Ministry of Food and Drug Safety (MFDS) announced this on the notifications of Orphan Drug Designation (ODD). Niktimvo (axatilimab)'s basis for ODD indication is for the treatment of 'adults an
- Company
- US postpones 'Drug Tariffs', but industry eyes the situation
- by Kim, Jin-Gu Apr 4, 2025 05:57am
- The US Trump administration announced reciprocal tariffs against the entire world, but “postponed” the application of tariffs on pharmaceuticals, because it is “considering separate industry-specific tariffs” on semiconductors, key minerals, and pharmaceuticals. The domestic pharmaceutical and bio industry is relieved for now but is
- Company
- Qarziba may be prescribed in general hospitals in KOR
- by Eo, Yun-Ho Apr 3, 2025 05:55am
- Qarziba, an immunotherapy drug that targets neuroblastoma, may now be prescribed at general hospitals in Korea. According to industry sources, Recordati Korea's immunotherapy drug for high-risk, recurrent, and refractory neuroblastoma, Qarziba Inj (dinutuximab beta), has passed the drug committees (DCs) of the ‘Big 5 general hospitals’
- Company
- "COVID-19 differs from influenza…vaccination essential"
- by Whang, byung-woo Apr 3, 2025 05:55am
- "COVID-19 can lead to 'long COVID,' and its progression tends to be more severe among the elderly and immunocompromised individuals. It is crucial to emphasize COVID-19 prevention as the saying goes, 'an ounce of prevention is worth a pound of cure.' After the announcement of the endemic in 2023, COVID-19 has repeatedly mutated, thus regarded
